Researchers have always concluded that results that do not support the hypothesis as unimportant, unworthy, or simply not good enough for publication. However, negative findings are essential for the progress of science and its self-correcting nature. We also believe in the importance and indispensability of negative results. Therefore, in this review, we discussed the factors contributing to the publication bias of negative results and the problems to assess the factuality and validity of negative results. Moreover, we emphasized the importance of reporting negative results in cardiovascular research, including treatments, and suggest that the negative results could clarify previously controversial topics in the treatment of cardiovascular diseases and prompt the translation of research on precision cardiovascular disease prevention and treatment.

Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide, with varied clinical and histopathological features between individuals, particularly across races. As an autoimmune disease, IgAN arises from consequences of increased circulating levels of galactose-deficient IgA1 and mesangial deposition of IgA-containing immune complexes, which are recognized as key events in the widely accepted \"multi-hit\" pathogenesis of IgAN. The emerging evidence further provides insights into the role of genes, environment, mucosal immunity and complement system. These developments are paralleled by the increasing availability of diagnostic tools, potential biomarkers and therapeutic agents. In this review, we summarize current evidence and outline novel findings in the prognosis, clinical trials and translational research from the updated perspectives of IgAN pathogenesis.

Endometrial cancer (EC) is the most common gynecological tumor in developed countries. Nowadays, molecular biomarkers have become increasingly important in the management of EC patients, helping in early detection, risk stratification, prognosis and response to the treatment, and qualification for novel immunotherapies, especially in EC patients with metastatic disease or recurrence. When EC tumor molecular profiling is combined with the standard histopathological features such as clinical stage, histologic grading and evaluation of lymphovascular space invasion, the final therapeutic outcome may bring benefits in terms of personalized and efficient management.

Integration of in vitro and in vivo investigations has brought the body of new emerging life sciences about. This inspirational domain needs a scientific platform to cover the relevant publications. BioImpacts (BI), as a peer-reviewed multidisciplinary international open access journal, intends to deal with all aspects of biological and biomedical researches at dimensions of molecular, cellular, functional and translational dimensions.